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Nitric oxide (NO) activates soluble guanylyl cyclase in smooth
muscle cells to induce vasodilation in the vasculature. However, as
hemoglobin (Hb) is an effective scavenger of NO and is present in
high concentrations inside the red blood cell (RBC), the bioavail-
ability of NO would be too low to elicit soluble guanylyl cyclase
activation in the presence of blood. Therefore, NO bioactivity must
be preserved. Here we present evidence suggesting that the RBC
participates in the preservation of NO bioactivity by reducing NO
influx. The NO uptake by RBCs was increased and decreased by
altering the degree of band 3 binding to the cytoskeleton. Met-
hemoglobin and denatured hemoglobin binding to the RBC mem-
brane or cytoskeleton also were shown to contribute to reducing
the NO uptake rate of the RBC. These alterations in NO uptake by
the RBC, hence the NO bioavailability, were determined to corre-
late with the vasodilation of isolated blood vessels. Our observa-
tions suggest that RBC membrane and cytoskeleton associated
NO-inert proteins provide a barrier for NO diffusion and thus
account for the reduction in the NO uptake rate of RBCs.
Extensive studies have established the bioactivity of nitricoxide (NO) in vasoregulation through activation of soluble
guanylyl cyclase (ref. 1 and references therein). On the other
hand, NO is rapidly deactivated by oxygenated hemoglobin
(HbO2) and myoglobin (MbO2) to form nitrate. As NO reacts
rapidly (k ; 107 M21zs21) with HbO2 and deoxygenated Hb
(deoxyHb), infusion of cell-free normoxic Hb (hereafter, Hb
denotes both HbO2 and deoxyHb) at mM levels into animal
models, human subjects, or isolated blood vessels (2–5) causes
significant vessel constriction due to NO scavenging. However,
normal blood containing RBC-encapsulated Hb (rbcHb) at an
equivalent concentration of about 10 mM shows insignificant
NO reactivity under physiological conditions (4, 6, 7). This
discrepancy is difficult to explain in view of the high permeability
of NO through lipid bilayers. Thus, NO bioactivity in blood must
be preserved by a yet unclear mechanism under physiological
conditions.
This problem recently was addressed by a NO bioactivity
export theory (8). According to this theory, NO enters the RBC
and preferentially binds with the free heme on Hb to form
heme-nitrosylHb (HbNO) rather than being oxidized by O2-
conjugated heme (9). HbNO then transfers the conjugated NO
to b-93Cys to form S-nitrosoHb (9). NO bioactivity is then
exported out of RBCs through the anion exchange protein, band
3 (or AE1). Although detailed mechanisms of SNO (S-
nitrosothiol species) formation and NO bioactivity export from
band 3 are still unclear (10, 11), the theory provides an expla-
nation for the preservation of NO bioactivity and highlights the
importance of the RBC in preserving NO bioavailability, which
has been suggested previously (12).
In parallel to the NO bioactivity export theory, an indepen-
dent, but not mutually exclusive, explanation that NO bioavail-
ability is preserved by reducing interactions between NO and
rbcHb has been proposed. This theory is based on diffusional
barriers between the NO-producing endothelium and rbcHb.
These barriers include (i) an unstirred boundary layer surround-
ing each RBC (13), (ii) a RBC-free layer at the vessel wall
induced by the flow of blood (4, 14, 15), and (iii) an unknown
RBC-intrinsic barrier for NO consumption (12). Independent
measurements using NO electrodes (13), microvessel bioassays
(4), or competition assays (12) have established that RBCs
consume NO at a rate ’800-fold lower than that of equivalent
concentration of free Hb. To account for this observation by the
NO export theory alone would require that NO be pumped out
of the RBC through a S-nitrosothiol species (SNO)-intermediate
at a rate almost as fast as NO influx. Otherwise, the NO influx
to RBC needs to be retarded. Given the relatively low rate of
transnitrosation reactions (10, 16), the reduction of NO influx is
more likely. Therefore, we suspected that the RBC possesses a
novel mechanism for preserving NO bioavailability in vivo.
In this article, we provide evidence that suggests that cytoskel-
etal and associated NO-inert proteins form a significant barrier
to retard NO influx into the RBC. This layer of NO-inert protein
accounts for a significant part of the difference between the NO
reactivity with RBCs and cell-free Hb. Further, by altering the
cytoskeleton and associated proteins, the RBC can be used to
modulate vessel tone through controlled NO scavenging. This
diffusion barrier also may explain S-nitrosothiol species (SNO)
formation in RBC and the data reported for oxygen uptake rate
of RBC.
Methods
Chemicals. Spermine NONOate, N-4-[1-(3-aminopropyl)-2-
hydroxy-2-nitrosohydrazino]butyl]-1,3-propanediamine was
purchased from Alexis (San Diego). Bis(sulfosuccinimidul)-
suberate (BS3) was from Pierce. Acetylphenylhydrazine
(APHZ), 4,49-diisothiocyanatostilbene-2,29-disulfonic acid
(DIDS), sodium azide, Sephadex G-25, a cellulose, microcrys-
talline cellulose, sodium dithionite, EDTA, Hepes, and BSA
were purchased from Sigma.
Preparation of Oxyhemoglobin and RBCs. All solutions for prepar-
ing proteins were chilled (4°C). The cell lysate was prepared by
lysing the purified RBCs with 5 mM sodium phosphate solution,
pH 8.0 (5P8) and centrifuging at 22,000 3 g, 4°C for 30 min.
HbO2 was isolated by passing the cell lysate through Sephadex
G-25 fine column (1.5 3 25-cm bed volume). Bovine, human, or
porcine blood was collected in heparinized (10 unitsyml) tubes.
The plasma and buffy coat were removed after centrifugation at
800 3 g for 10 min. The cells were resuspended and washed four
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times in Hepes buffer containing 140 mM NaCl, 20 mM Hepes,
5 mM glucose (pH 7.4), 290 mOsmolykg. After each wash, the
cells were centrifuged at 800 3 g for 10 min. The RBCs were
purified by filtration through a mixture of a cellulose and
microcrystalline cellulose (17).
BS3 Pretreatment. RBC suspensions [22.5 ml, 15% hematocrit, in
Dulbecco’s phosphate buffer solution (DPBS) containing 5 mM
glucose] in a 30-ml syringe was deoxygenated by bubbling with
nitrogen or argon for 2 h. BS3 dissolved in DMSO was then
added to the RBC suspension to achieve a final concentration of
1 mM. After 15 min of bubbling nitrogen at 22°C, the syringe was
transferred to a nutator (Clay Adams) for 45 min. The treated
RBCs were washed twice with DPBS containing 10 mM etha-
nolamine and reoxygenated by bubbling with air for 15 min. The
RBCs were further washed twice with isotonic Hepes buffer
containing 5 gyliter BSA and three times with isotonic Hepes
buffer.
DIDS Pretreatment. A RBC suspension (15% hematocrit) was
incubated with 100 mM DIDS at 22°C for 1 h. The treated cells
were washed twice with isotonic Hepes buffer containing 5
gyliter BSA, and then three times with isotonic Hepes buffer.
Sodium Azide Pretreatment. RBCs (15% hematocrit) were incu-
bated with 0.1 mM NaN3 for 1 h. Cells were washed five times
with Hepes buffer (10-fold dilution). As azide binding of met-
hemoglobin (metHb) alters the spectra, an additional control
was used during the competition assay. This control consisted of
azide-pretreated RBCs in a 10 mM solution of Hb; the Hb
solution was a 50y50 mixture of HbO2 and metHb. A decrease
in the amount of metHb in this control is indicative of azide
leakage from the treated RBCs caused by inadequate washing of
treated cells. Samples exhibiting azide leakage were discarded.
Control cells were processed parallel to treated cells.
APHZ Pretreatment. Fifteen milliliters of washed RBC suspension
(15% hematocrit) was exposed to APHZ (15 mM) for 2 h at
37°C. Cells were then washed three times in isotonic Hepes.
Detection of Heinz bodies was confirmed by light microscopy
after crystal violet staining.
NO Gas Pretreatment. NO gas (Matheson) was purified by bub-
bling through deoxygenated NaOH (5 M) as described (18). NO
gas was also produced by mixing equal volumes of 1 M HCl and
1 M NaNO2 in a syringe sealed with a septum; the reaction was
stopped and higher oxides of nitrogen were removed by adding
1 vol of 5 M NaOH. NO gas (0.1–0.9 ml) was added to 15 ml of
RBC suspension (15% hematocrit) contained in a 20-ml syringe.
The syringe was placed on a mixer for 1 h. After treatment, the
RBCs were washed at least four times in Hepes buffer.
The Competition Assay for Measuring NO Uptake Rate by RBCs. This
procedure has been described (12, 19). A detailed description of
the procedure along with a computer program for calculating the
kinetic constant is available online (http:yywww.seas.ucla.eduy
;liaoj). Under this experimental condition, no S-nitrosoHb or
heme-nitrosyl Hb was detected by using an independent ozone-
based chemiluminescent detection (20). The rate constant (kRBC,
or k9RBC) for NO consumption by RBC was defined in the
following equation
VRBC 5 kRBC[rbcHb][NO] 5 k9RBC[RBC][NO],
where VRBC is the rate of NO consumption by RBCs, [rbcHb],
and [NO] are the concentrations of total RBC heme and NO,
respectively, based on the total volume as if Hb was not enclosed
by the RBC membrane. The first definition allows the compar-
ison between kRBC with kHb (rate constant for the reaction
between NO and free HbO2) on the same homogeneous basis.
With this definition, kRBC was calculated according to the
method reported previously (12, 19). To determine the NO
consumption on a per-RBC basis, we used the second definition
in the above equation, where [RBC] is the number of RBC per
unit volume. Therefore, k9RBC can be calculated from kRBC,
k9RBC 5 kRBC [rbcHb]y[RBC]. The RBC cell density was 3.0 3
106yml for 15% hematocrit of normal bovine RBCs.
Microvessel Bioassay. The techniques for isolation of porcine
coronary microvessels have been described (21). Subepicardial
arteriolar branches (50–100 mm in internal diameter in situ) were
dissected from the surrounding cardiac tissue, transferred to a
vessel chamber, and then cannulated with glass micropipettes on
a micromanipulation platform. After cannulation, the vessel and
chamber were transferred to the stage of an inverted microscope
coupled to a charge-coupled device camera, video micrometer,
and video recorder. The intraluminal pressure of the vessels was
controlled by connecting the micropipettes to independent
reservoir systems. The vessel was incubated at 37°C and pres-
surized to 60 cm H2O luminal pressure without flow. After
developing a basal tone, buffer, RBCs, or treated-RBCs were
introduced into the lumen, and the internal diameter of the
vessel was continuously recorded. Serotonin (0.1 mM) was added
to the vessel bath to induce vessel dilation.
Preparation of Resealed Ghosts Containing Different Hb Concentra-
tions. Resealed ghosts containing cytosolic Hb less than 200 mM
were prepared following the methods of Steck and Kant (22)
with some modification. Briefly, 28 ml of 5P8 buffer at 4°C was
added to 4 ml of 50% hematocrit RBC suspension in Hepes
buffer. The sample was left on ice for 5 min then centrifuged at
22,000 3 g (max), 4°C for 40 min. The pellet was washed,
resuspended, and centrifuged four times by using 12 ml of 5P8
at 22,000 3 g, 4°C for 20 min. The red cell pellet (membrane) was
incubated on ice for 30 min in various concentrations of RBC
lysate or purified bovine HbO2. A 5 M NaCl solution was used
to adjust the osmolarity to 290 mOsmykg. The ghost membrane
was sealed by incubation at 37°C for 40 min. The sealed ghost was
centrifuged at 6,700 3 g for 20 min and then equilibrated with
Hepes buffer at 4°C overnight. For cytosolic Hb higher than 200
mM, RBCs were lysed by gradually adding 8–16 ml of 5P8 to 4
ml of 50% hematocrit RBC suspension. Osmolarity adjustment
and the sealing process was the same as that for the low-range
Hb preparation.
Viscosity Modification. The buffer viscosity was increased by the
addition of polyethylene glycol (average molecular weight 5
8,000; Fisher Scientific) while the osmolarity was held constant
at 290 mOsm by adjusting the concentration of NaCl. A falling
ball viscometer was used to measure viscosity.
Results
Modification of Band 3 Affects NO Uptake Rate. Band 3 is responsible
for a host of functions ranging from anion transport to support-
ing the cytoskeleton by binding with ankyrin (23). The NO
export theory suggests that band 3 exports NO bioactivity
because inhibition of band 3 activity reduced NO bioactivity in
nearly anaerobic conditions (1% oxygen saturation) (8). Under
normoxic conditions NO bioactivity export by band 3 was not
demonstrated (8). To characterize the involvement of band 3 in
the RBC intrinsic barrier, band 3 was perturbed with crosslinkers
BS3 and DIDS, both of which inhibit anion transport activity and
alter band 3 binding with cytoskeletal proteins (24). The NO
uptake rate was measured by use of the competition assay (19)
under normoxic conditions. The NO uptake rate constant (kRBC)
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of BS3-treated RBCs decreased ’50%, whereas kRBC for the
DIDS-treated RBCs increased ’15% (Fig. 1a). Because of the
changes in NO uptake that resulted from perturbing band 3, it
is highly likely that this membrane-associated protein plays a role
in regulating NO uptake, in addition to NO bioactivity export
(8). However, opposite effects on NO uptake by BS3 and DIDS
(both band 3 inhibitors) suggest that mechanisms other than the
anion exchange activity of band 3 may be involved in modulating
the NO uptake rate. A difference between the manner in which
BS3 and DIDS act on band 3 is that the former shifts the band
3 population toward tetramers (25), which promotes cytoskele-
ton binding through band 3 binding with ankyrin, whereas the
latter shifts the population of band 3 to dimers, which weakens
cytoskeleton binding (26). As the state of band 3 directly
influences the association of ankyrin, and in turn the cytoskel-
eton, this submembrane protein layer may retard the diffusion
of NO.
Heinz Body and metHb Binding to Cytoskeletal Proteins Reduces NO
Uptake Rate. If cytoskeletal proteins are involved in the retarda-
tion of NO transport, one should be able to alter the NO uptake
rate by perturbing interprotein associations in the cytoskeleton.
The binding of several intraerythrocytic proteins, such as Hb,
hemichrome, and Heinz bodies, to the membrane has been well
documented (27, 28). APHZ is a common reagent for forming
Heinz bodies that bind to the cytoskeleton (29). If the cytoskel-
eton is a ‘‘semiporous’’ barrier, APHZ should decrease the NO
uptake rate as the formation of Heinz bodies would fill in some
voids. Indeed, treatment of human RBCs with APHZ resulted in
a decrease in the NO uptake rate (Fig. 1a). Interestingly, APHZ
did not affect the NO uptake rate of bovine RBCs (data not
shown) and no Heinz bodies were detected.
MetHb binds more strongly to the membrane and associated
proteins than other Hb species (30). Because metHb has a lower
reactivity toward NO (than HbO2, deoxygenated Hb, soluble
guanylyl cyclase, etc.), its binding to the membrane and cytoskel-
etal proteins can further retard the diffusion of NO. If metHb
contributes to the membrane protein barrier then dissociating
metHb from the membrane should increase the NO consump-
tion rate by RBCs. To test this hypothesis, we treated RBCs with
sodium azide, which binds to and then dissociates metHb from
the membrane (30). After washing several times to remove
unbound azide, the treated RBCs were tested with the compe-
tition assay. Remarkably, azide pretreatment increased kRBC
2-fold in bovine, 40% in human blood, and about 15% in porcine
blood (Fig. 1b). These data support the hypothesis that metHb
is involved in the membrane protein barrier. In all of the above
competition assays, we simultaneously conducted various con-
trol experiments to show that the observed effect is not an
artifact caused by increased autooxidation of Hb or metHb
reduction. We also have used transmission electron microscopy
to show that these chemical modifications did not alter RBC
morphology (data not shown). Note that the effect of azide
treatment may be underestimated because the RBC was washed
several times after azide treatment to avoid azide binding with
extracellular metHb, which would skew the absorbance spec-
trum. After washing, the concentration of azide in the RBC was
much lower than the initial concentration.
To demonstrate that membrane-bound metHb could be a
component of a dynamic barrier, we treated RBCs with azide to
release metHb and then NO gas to increase the amount of
membrane-associated metHb and vice versa. We found that NO
gas treatment after azide treatment abolished the azide effect
and even decreased the NO uptake rate by about 20% (Fig. 1c).
Interestingly, we found that treatment of RBCs with NO gas
alone elicited about the same decrease ’20%, and subsequent
treatment with azide only returned the NO uptake rate to near
baseline. It is known that high concentrations of NO oxidize and
denature Hb, forming both metHb and Heinz bodies, both of
which are associated with the membrane and cytoskeletal pro-
teins. Because azide can release metHb from the membrane but
has little effect on Heinz bodies, it is reasonable to see that it only
partially reverses the effect of NO treatment on kRBC.
Functional Role of RBC in Microvascular Regulation. To test whether
the alteration of kRBC demonstrated above has a functional role
in vascular regulation, we used isolated porcine coronary mi-
crovessels as a bioassay. The isolated artierioles developed basal
tone (62 6 1% of maximum diameter) at 37°C and the diameters
were continuously recorded. Serotonin was used to evaluate
NO-mediated vascular function. Serotonin is known to exert
endothelium-dependent NO-mediated vasodilation in the intact
coronary arterioles (31) but produces vasoconstriction in the
denuded vessel (32) through direct activation of 5-HT2 seroto-
nergic receptor in vascular smooth muscle cells. When serotonin
was added to the vessel without RBC in the lumen, the vessel
Fig. 1. Uptake of NO by RBCs can be altered by perturbing the cytoskeleton
and associated proteins. Relative kRBC represents kRBCykRBC,Control. (a) BS3 treat-
ment, which shifts the band 3 population toward tetramers (increased cy-
toskeletal binding), decreased the kRBC of porcine RBCs. Treatment of porcine
RBCs with DIDS (decreased cytoskeletal binding) increased kRBC by 20%. APHZ
(15 mM), which promotes the formation of Heinz bodies that can bind to the
cytoskeleton, decreased kRBC of human RBCs by 20%. (b) Treatment of RBCs
with 0.1 mM sodium azide increased the NO uptake rate in three different
species: porcine, human, and bovine. (c) Treatment of bovine RBCs (15% Hct)
with azide (100 mM) increased kRBC 2-fold. Subsequent treatment with NO gas
(azide 1 NO, 300 mM final concentration), which oxidizes membrane-bound
and free HbO2, abolished the azide effect. Treatment with NO gas (NO, 300
mM) decreased kRBC by 25%. Subsequent treatment with azide (NO 1 azide,
100 mM) returned kRBC to the baseline. NO gas treatment oxidized ’70% of
intracellular hemoglobin. (n 5 3–7). *, P , 0.05 vs. control; 1, P , 0.05. Less
than 0.05 mM of NO species (heme-nitrosylHb and nitrosothiol) were formed
in the extracellular space.
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dilated within a few seconds (Fig. 2a). However, the dilation
elicited by serotonin was attenuated when untreated RBCs are
present in the lumen. These data are consistent with our previous
finding in coronary arterioles (6). When BS3-RBCs (which
exhibit a decreased kRBC) were in the lumen, the NO-mediated
vessel dilation was enhanced relative to the untreated RBCs.
This result shows that the measurement of RBC consumption of
NO with the competition assay is physiologically relevant. Con-
sequently, DIDS-treated RBCs (which have an increased NO
consumption) caused vessel constriction rather than dilation. A
similar effect is also seen when azide-pretreated RBCs (which
increased kRBC) were in the lumen (Fig. 2b). Because azide and
DIDS elicited an increase (i.e., 15%) in kRBC and correspond-
ingly abolished serotonin-mediated vasodilation, it appears that
the vascular function is tightly regulated by NO through a
relatively small change in kRBC. As controls, we observed that
supernatants from RBCs suspensions (both treated and un-
treated RBCs) did not change the vessel tone, indicating that the
alteration of vessel regulation is not caused by chemical species
leaking out of RBCs.
NO Consumption as a Function of Intraerythrocytic Hb. Although
strong evidence linking the cytoskeleton and its associated
proteins to the NO consumption rate of the RBC has been
presented, intracellular reactions may have a role in regulating
NO uptake. To rule out the possibility of intracellular reaction
control, we prepared RBC ghosts containing 0–1 mM Hb.
Modifed RBCs were achieved either by gradual lyses (0.3–1 mM
Hb) or purifying the RBC ghosts and then resealing them in the
presence of various concentrations of RBC lysate or purified Hb.
The NO consumption rate of the modified RBCs was measured
with the competition assay. The modified RBC was sufficiently
stable that insignificant lysis occurred. The rate constant for NO
consumption by RBCs was calculated based on the number
density of RBCs (k9RBC). We found that the NO consumption
rate remained constant when the intraerythrocytic Hb concen-
tration decreased from 20 mM to about 0.2 mM. Below 0.2 mM,
the NO consumption rate decreased when the intraerythrocytic
Hb concentration decreased (Fig. 3). These results demonstrate
that the intracellular Hb concentration is not a limiting factor for
NO consumption in normal RBCs. The intracellular Hb be-
comes limiting only when its concentration is lower than 0.2 mM.
Thus, intracellular reaction rate is not a limiting factor for NO
consumption under physiological conditions.
Diffusion Resistance in Extracellular Undisturbed Layer Is Not Domi-
nating. Another possible factor limiting NO consumption by
RBCs is the diffusional resistance caused by the undisturbed
boundary layer around each RBC (13). If extracellular diffusion
is dominating, kRBC measured by the competition assay should be
a strong function of viscosity. We therefore measured kRBC in
buffers with increased concentrations of polyethylene glycol,
which increased the buffer viscosity. The diffusivity of a mole-
cule in liquids is known to be inversely proportional to the
viscosity (33). Within small changes (50% increase in viscosity)
kRBC was not a function of viscosity (Fig. 4). When the viscosity
was increased by 2-fold, kRBC decreased by 20%. These results
Fig. 2. Chemically treated RBCs modulate serotonin-induced vasodilation.
(a) Representative polygraph trace of porcine vessel experiment. When sero-
tonin (0.1 mM) alone is added to the vessel bath, the vessel dilated within a few
seconds. The addition of untreated RBCs to the lumen attenuated the sero-
tonin-induced vasodilation. Infusion of DIDS-pretreated RBCs abolished the
serotonin-induced vasodilation and elicted 15% vasoconstriction. (b) The
vasoactivity of the treated RBCs followed the trends exhibited in the kRBC
measurements (Fig. 1). BS3 pretreatment attenuated the inhibition of seroto-
nin-induced vasodilation, indicative of a decreased NO uptake rate. DIDS and
azide pretreatments induced vasoconstriction, indicative of an increased NO
uptake rate. The hematocrit for all experiments was 50% (n 5 3–5); *, P , 0.05
vs. control.
Fig. 3. NO uptake rate as a function of intraerythrocytic Hb concentration;
k9RBC is the NO uptake constant on a per-RBC basis. The NO uptake rate is
independent of intracellular Hb for concentrations greater than 0.2 mM (20
mM is physiologic). These data were consistent with the prediction of our
mathematical model (12) developed by using independent data and an esti-
mated membrane permeability (415 mmzs21) ’1,000-fold lower than that of a
lipid bilayer (n 5 3–7).
Fig. 4. Relative kRBC (kRBCykRBC,Control) as a function of extracellular viscosity.
Increasing the extracellular viscosity of RBC solutions by 50% did not signifi-
cantly change the NO uptake rate (P 5 0.24). A 2-fold increase in extracellular
viscosity decreased NO uptake by 15 6 6 (SD) % [*, P , 0.05 versus 1.04
centipoise (cp) sample]. Physiologic blood plasma viscosity is ’1.23 cp. n 5 3–4.
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showed that extracellular diffusion is not the dominating factor
in the kRBC measurement.
Discussion
The preservation of NO bioactivity in the vasculature is required
to reconcile the vasoregulatory role of NO in the presence of mM
concentrations of RBC-encapsulated Hb. We and others have
shown that diffusion barriers exist between the site of NO
production and the RBC-encapsulated Hb (4, 12–14). Here we
provide evidence that suggests the possibility of cytoskeleton and
associated NO-inert proteins as members of a submembrane
resistance to the entry of NO (Fig. 5). As a result of this
resistance, kRBC for NO is reduced to 3 3 104 M21zs21, which is
about 3 orders of magnitude lower than kHb (’107 M21zs21). The
rate constant for NO uptake by RBCs is remarkably close to the
value of kRBC for oxygen uptake (6.9 3 104 M21zs21), which is
about 40-fold slower than reaction with free deoxygenated Hb
(34). This result is consistent with a previous report that NO and
O2 diffuse into the RBC at similar rates (34). It is likely that the
same barrier retards both NO and O2 entry into the cell.
Limitation of O2 uptake by RBCs was attributed to the extra-
cellular unstirred layer formed in the stopped-flow experiment
(34, 35). However, membrane limitation cannot be conclusively
ruled out. The existence of membrane limitation is supported by
the following results. (i) The kRBC value for NO uptake can be
changed by various chemical modifications of RBCs without
changing morphology. (ii) Alteration of buffer viscosity (and
thus molecular diffusivity) does not change the value of kRBC
significantly. (iii) Reduction of intracellular Hb concentration
over 2 orders of magnitude does not change kRBC. These results
suggest against the possibilities of intracellular Hb limitation and
extracellular diffusion limitation. In addition, the competition
assay we used has been shown to be insensitive to extracellular
diffusion because of the use of homogenous NO donors and the
high hematocrit in the assay (12). The existence of this mem-
brane barrier preserves NO bioavailability and might, at least
partially, explain the diffusional resistance to oxygen uptake that
was previously attributed to an extracellular unstirred layer.
The nature of this diffusion resistance is deduced from the
above experimental results (Fig. 5). On the cytosolic side of the
membrane (submembrane) there is a cytoskeletal network of
proteins, including spectrin, metHb, and denatured Hb that are
relatively NO-inert (23). This protein network provides surface
coverage on the order of magnitude of the RBC surface area (23)
and could provide a path sufficiently tortuous to significantly
slow the diffusion of small molecules such as NO. RBC cytoskel-
etal spectrin alone could cover well over half of the cytosolic face
of the RBC membrane (23). Normal RBCs contain 1% metHb,
which is sufficient to cover the entire membrane (27). When all
of the proteins that make up the cytoskeleton (spectrin, band 3,
actin, ankyrin, band 4.1, metHb, and denatured Hb) are taken
into account, the existence of a dense submembrane layer that
completely covers the inner membrane is likely (36). In fact,
spectrin at in vivo cytoskeletal concentrations has been found to
form a gel in vitro (23).
The submembrane protein network is anchored on the trans-
membrane protein band 3. Treatment of RBCs with band 3
crosslinkers (BS3 and DIDS) that perturb the cytoskeleton
altered the NO uptake rate. BS3 and DIDS are also well-
characterized band 3 inhibitors. If NO bioactivity is preserved
based on NO export through band 3, inhibition of band 3 activity
(by either BS3 or DIDS) should increase the apparent NO
consumption rate dramatically. However, DIDS treatment in-
creases kRBC by only 15%, whereas BS3 treatment decreases kRBC
by 50%. Because these band 3 inhibitors have opposite effects on
NO uptake, inhibition of band 3 activity cannot explain the
changes in kRBC observed. Instead, the explanation lies in the
effects of BS3 and DIDS on the membrane cytoskeleton. BS3
treatment shifts the band 3 population toward tetramers (25),
which enhance binding of band 3 to ankyrin, a protein that
anchors the cytoskeleton to the membrane (26). This binding is
weakened when the band 3 population is shifted to dimers, as
occurs in the case of DIDS treatment (26). These effects on
ankyrin binding to band 3 directly impact the NO uptake rate of
the RBC and support our theory that the cytoskeleton is a
diffusion barrier to physiological concentrations of NO.
Binding of Hb to the cytoskeletal network is well characterized
(27, 37, 38). Among the Hb species, the membrane and cytoskel-
etal network preferentially bind metHb (30), which binds with
NO at a much lower rate (k ; 104 M21zs21) (39–41). Because of
the relatively low reactivity of metHb with NO, metHb can
contribute to a barrier to the diffusion of NO, thus reduce the
NO uptake rate. Unbound metHb has little effect on kRBC, as
demonstrated previously (13). The involvement of bound metHb
and denatured Hb in the diffusion barrier is supported by
treatments that increase (APHZ, NO gas) or decrease (azide)
the binding of metHb and NO-inert Hb species to the cytoskel-
eton and associated proteins. Treatment with APHZ or NO gas,
which oxidize and denature Hb to form metHb and Heinz
bodies, are known to increase the amount of these species bound
to the cytoskeletal network (29). As expected, APHZ or NO gas
pretreatment decreased kRBC.
Treatment with azide released the metHb from the membrane
(30) and thus increased the NO uptake rate constant. Azide is
a high affinity ligand for metHb. Once azide binds metHb, the
Hb-N3 complex is released from the membrane (30) and should
create gaps in the submembrane barrier. When treated with
azide followed by washing, the NO uptake rate was found to
increase for bovine, porcine, and human RBCs and was further
validated with the vessel bioassay. As azide treatment had a
common effect over three species, this finding demonstrates the
commonality of this mode of NO regulation.
The implications of a cytoskeletal barrier to the diffusion of
NO can be far reaching. We have demonstrated that RBCs can
Fig. 5. Schematic of the hypothetical membrane barrier to NO uptake. The
RBC retards small gas molecules such as NO from entering with a submem-
brane barrier built up around the unique RBC-cytoskeleton. Small molecules
are able to cross the barrier through interprotein gaps (pores), but with a
much reduced rate. These pores can be loosened or tightened by adjusting the
tension in the cytoskeletal structure or plugged with NO-inert proteins.
Increasing the tension by strengthening the association of the cytoskeleton to
the membrane tightens the cytoskeletal structure and closes the pores, which
effectively slows NO entry. Decreasing the tension creates slack in the cytoskel-
eton, which opens pores and increases the number of entry points for NO.
These pores can be plugged with Heinz bodies or metHb (induced by APHZ or
NO gas treatment); the metHb plugs can be removed with azide.
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be chemically modified to modulate NO bioactivity, and that
these modifications have functional roles in vascular regulation.
The isolated vessel experiments not only substantiate the kRBC
measurements using competition assays, but also provide evi-
dence that RBCs play a role in vessel regulation by preserving
NO bioactivity. Further, this barrier in the submembrane space
may contribute to the accumulation of NO in the membrane
(42), which may then react with O2 to form nitrosating agents,
such as N2O3. These nitrosating agents could then react with the
b-93-cys of membrane-bound Hb or band 3 thiol groups to form
S-nitrosothiols. Although a dynamic regulation of NO uptake by
the RBC is speculative, these results imply that chemically
modified RBCs can be used as NO scavengers or NO preservers.
Moreover, Hb-based blood substitutes are insufficient and can-
not emulate RBCs without a barrier to the diffusion of NO.
Thus, the RBC intrinsic barrier to NO may be required to truly
emulate RBC functions in the vasculature.
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